On Thursday, March 1, Sanofi announced that it has received antitrust clearances in the US and Germany in connection with its proposed acquisition of Ablynx.
Sanofi said that a waiting period for its proposed acquisition of Ablynx had expired without objections being raised. Under the US Hart-Scott-Rodino Antitrust Improvements Act, parties to certain transactions must submit notification to the country’s Federal Trade Commission and Department of Justice and wait before the transaction can be completed.
The proposed acquisition has also been cleared by the Federal Cartel Office (FCO) of Germany, the French pharmaceutical company said.
With the expiration of the waiting period and the FCO clearance, “the condition to the offers relating to antitrust approvals has been satisfied,” Sanofi said.
Full Content: Market Watch
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UFC Reaches $375 Million Settlement in Antitrust Case
Feb 6, 2025 by
CPI
Brazilian Architecture Council Convicted of Antitrust Violations
Feb 6, 2025 by
CPI
Bipartisan Bill Seeks to Ban Chinese AI Software from US Government Devices
Feb 6, 2025 by
CPI
Senators Call for Investigation into RealPage Algorithm’s Impact on Military Housing Costs
Feb 6, 2025 by
CPI
ECB Seeks Faster Digital Euro Legislation Amid US Stablecoin Push
Feb 6, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon